Michael Weichenthal
Overview
Explore the profile of Michael Weichenthal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
151
Citations
5611
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Forschner A, Kahler K, Gschnell M, Langan E, Weishaupt C, Meiss F, et al.
Front Immunol
. 2025 Mar;
16:1509886.
PMID: 40066437
Background: Although systemic therapies have improved considerably over the last decade, up to 50% of patients with metastatic melanoma still die due to disease progression. Oncological treatment at the end-of-life...
2.
Placke J, Rajcsanyi L, Herbst R, Terheyden P, Utikal J, Pfohler C, et al.
Front Immunol
. 2025 Mar;
16:1536642.
PMID: 40028330
Background: Modern therapeutic strategies have significantly improved the prognosis of advanced melanoma patients. Predictive factors of therapy response include serum LDH; however, predictive markers for long-term survival are currently largely...
3.
Hauschild A, Garbe C, Ascierto P, Demidov L, Dreno B, Dummer R, et al.
Lancet Oncol
. 2025 Jan;
26(1):12-14.
PMID: 39756440
No abstract available.
4.
Kott J, Zell T, Zimmermann N, Runger A, Smit D, Abeck F, et al.
Eur J Cancer
. 2024 Dec;
214():115159.
PMID: 39642845
Background: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing anti-tumor treatment is through...
5.
Lang B, Balermpas P, Bauer A, Blum A, Dirschka T, Follmann M, et al.
J Dtsch Dermatol Ges
. 2024 Nov;
22(12):1697-1714.
PMID: 39584658
Basal cell carcinoma is the most common malignant tumor in the fair-skinned population and its incidence continues to rise. An update of the S2k guideline with the participation of all...
6.
Weichenthal M, Mangana J, Gavrilova I, Lugowska I, Shalamanova G, Kandolf L, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39517999
Background: Although data on patients treated with pembrolizumab are available from clinical trials and single-country real-world reports, to our knowledge no multi-country real-world studies have investigated the use of pembrolizumab...
7.
Lodde G, Zhao F, Herbst R, Terheyden P, Utikal J, Pfohler C, et al.
Eur J Cancer
. 2024 Aug;
210:114295.
PMID: 39213786
Background: Immune checkpoint inhibition (ICI) currently is the most effective treatment to induce durable responses in metastatic melanoma. The aims of this study are the characterization of patients with early,...
8.
Jansen P, Galetzka W, Lodde G, Standl F, Zaremba A, Herbst R, et al.
Eur J Cancer
. 2024 Jul;
208:114208.
PMID: 39018633
Background: Melanomas lacking mutations in BRAF, NRAS and NF1 are frequently referred to as "triple wild-type" (tWT) melanomas. They constitute 5-10 % of all melanomas and remain poorly characterized regarding...
9.
Wohlfeil S, Kranzmann L, Weiss C, von Wasielewski I, Klespe K, Kahler K, et al.
Int J Cancer
. 2024 Jul;
155(10):1808-1823.
PMID: 38975881
This study investigated whether adjuvant treatments in stage III cutaneous melanoma (CM) influenced patterns of recurrence. Patients with primary (n = 1033) or relapsed CM (n = 350) who received...
10.
Koch E, Petzold A, Dippel E, Erdmann M, Gesierich A, Gutzmer R, et al.
Front Immunol
. 2024 Jun;
15:1395225.
PMID: 38915414
Introduction: Despite recent advancements in the treatment of metastatic uveal melanoma (UM), the availability of further treatment options remains limited and the prognosis continues to be poor in many cases....